A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

Guido Finazzi, Alessandro M. Vannucchi, Vincenzo Martinelli, Marco Ruggeri, Francesco Nobile, Giorgina Specchia, Enrico Maria Pogliani, Odoardo Maria Olimpieri, Giuseppe Fioritoni, Caterina Musolino, Daniela Cilloni, Piera Sivera, Giovanni Barosi, Maria Chiara Finazzi, Silvia Di Tollo, Tim Demuth, Tiziano Barbui, Alessandro Rambaldi

Research output: Contribution to journalArticle

Abstract

Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia vera (PV), unresponsive to the maximum tolerated doses (MTD) of hydroxycarbamide (HC), were treated with Givinostat (50 or 100 mg/d) in combination with MTD of HC. The European LeukaemiaNet response criteria were used to assess the primary endpoint after 12 weeks of treatment. Complete or partial response was observed in 55% and 50% of patients receiving 50 or 100 mg of Givinostat, respectively. Control of pruritus was observed in 64% and 67% of patients in the 50 and 100 mg groups, respectively. The combination of Givinostat and HC was well tolerated: eight patients (18%) discontinued, four in each treatment arm; grade 3 adverse events were reported in one patient (4·5%) in each treatment arm. The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients.

Original languageEnglish
Pages (from-to)688-694
Number of pages7
JournalBritish Journal of Haematology
Volume161
Issue number5
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Polycythemia Vera
Maximum Tolerated Dose
Histone Deacetylase Inhibitors
Pruritus
givinostat
Therapeutics
Cell Proliferation
Mutation

Keywords

  • Givinostat
  • Histone-deacetylase inhibitor
  • Hydroxycarbamide
  • Myeloproliferative neoplasm
  • Polycythaemia vera

ASJC Scopus subject areas

  • Hematology

Cite this

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. / Finazzi, Guido; Vannucchi, Alessandro M.; Martinelli, Vincenzo; Ruggeri, Marco; Nobile, Francesco; Specchia, Giorgina; Pogliani, Enrico Maria; Olimpieri, Odoardo Maria; Fioritoni, Giuseppe; Musolino, Caterina; Cilloni, Daniela; Sivera, Piera; Barosi, Giovanni; Finazzi, Maria Chiara; Tollo, Silvia Di; Demuth, Tim; Barbui, Tiziano; Rambaldi, Alessandro.

In: British Journal of Haematology, Vol. 161, No. 5, 06.2013, p. 688-694.

Research output: Contribution to journalArticle

Finazzi, G, Vannucchi, AM, Martinelli, V, Ruggeri, M, Nobile, F, Specchia, G, Pogliani, EM, Olimpieri, OM, Fioritoni, G, Musolino, C, Cilloni, D, Sivera, P, Barosi, G, Finazzi, MC, Tollo, SD, Demuth, T, Barbui, T & Rambaldi, A 2013, 'A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy', British Journal of Haematology, vol. 161, no. 5, pp. 688-694. https://doi.org/10.1111/bjh.12332
Finazzi, Guido ; Vannucchi, Alessandro M. ; Martinelli, Vincenzo ; Ruggeri, Marco ; Nobile, Francesco ; Specchia, Giorgina ; Pogliani, Enrico Maria ; Olimpieri, Odoardo Maria ; Fioritoni, Giuseppe ; Musolino, Caterina ; Cilloni, Daniela ; Sivera, Piera ; Barosi, Giovanni ; Finazzi, Maria Chiara ; Tollo, Silvia Di ; Demuth, Tim ; Barbui, Tiziano ; Rambaldi, Alessandro. / A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. In: British Journal of Haematology. 2013 ; Vol. 161, No. 5. pp. 688-694.
@article{42455387af7940e1bd5b16da023adf8b,
title = "A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy",
abstract = "Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia vera (PV), unresponsive to the maximum tolerated doses (MTD) of hydroxycarbamide (HC), were treated with Givinostat (50 or 100 mg/d) in combination with MTD of HC. The European LeukaemiaNet response criteria were used to assess the primary endpoint after 12 weeks of treatment. Complete or partial response was observed in 55{\%} and 50{\%} of patients receiving 50 or 100 mg of Givinostat, respectively. Control of pruritus was observed in 64{\%} and 67{\%} of patients in the 50 and 100 mg groups, respectively. The combination of Givinostat and HC was well tolerated: eight patients (18{\%}) discontinued, four in each treatment arm; grade 3 adverse events were reported in one patient (4·5{\%}) in each treatment arm. The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients.",
keywords = "Givinostat, Histone-deacetylase inhibitor, Hydroxycarbamide, Myeloproliferative neoplasm, Polycythaemia vera",
author = "Guido Finazzi and Vannucchi, {Alessandro M.} and Vincenzo Martinelli and Marco Ruggeri and Francesco Nobile and Giorgina Specchia and Pogliani, {Enrico Maria} and Olimpieri, {Odoardo Maria} and Giuseppe Fioritoni and Caterina Musolino and Daniela Cilloni and Piera Sivera and Giovanni Barosi and Finazzi, {Maria Chiara} and Tollo, {Silvia Di} and Tim Demuth and Tiziano Barbui and Alessandro Rambaldi",
year = "2013",
month = "6",
doi = "10.1111/bjh.12332",
language = "English",
volume = "161",
pages = "688--694",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

AU - Finazzi, Guido

AU - Vannucchi, Alessandro M.

AU - Martinelli, Vincenzo

AU - Ruggeri, Marco

AU - Nobile, Francesco

AU - Specchia, Giorgina

AU - Pogliani, Enrico Maria

AU - Olimpieri, Odoardo Maria

AU - Fioritoni, Giuseppe

AU - Musolino, Caterina

AU - Cilloni, Daniela

AU - Sivera, Piera

AU - Barosi, Giovanni

AU - Finazzi, Maria Chiara

AU - Tollo, Silvia Di

AU - Demuth, Tim

AU - Barbui, Tiziano

AU - Rambaldi, Alessandro

PY - 2013/6

Y1 - 2013/6

N2 - Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia vera (PV), unresponsive to the maximum tolerated doses (MTD) of hydroxycarbamide (HC), were treated with Givinostat (50 or 100 mg/d) in combination with MTD of HC. The European LeukaemiaNet response criteria were used to assess the primary endpoint after 12 weeks of treatment. Complete or partial response was observed in 55% and 50% of patients receiving 50 or 100 mg of Givinostat, respectively. Control of pruritus was observed in 64% and 67% of patients in the 50 and 100 mg groups, respectively. The combination of Givinostat and HC was well tolerated: eight patients (18%) discontinued, four in each treatment arm; grade 3 adverse events were reported in one patient (4·5%) in each treatment arm. The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients.

AB - Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia vera (PV), unresponsive to the maximum tolerated doses (MTD) of hydroxycarbamide (HC), were treated with Givinostat (50 or 100 mg/d) in combination with MTD of HC. The European LeukaemiaNet response criteria were used to assess the primary endpoint after 12 weeks of treatment. Complete or partial response was observed in 55% and 50% of patients receiving 50 or 100 mg of Givinostat, respectively. Control of pruritus was observed in 64% and 67% of patients in the 50 and 100 mg groups, respectively. The combination of Givinostat and HC was well tolerated: eight patients (18%) discontinued, four in each treatment arm; grade 3 adverse events were reported in one patient (4·5%) in each treatment arm. The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients.

KW - Givinostat

KW - Histone-deacetylase inhibitor

KW - Hydroxycarbamide

KW - Myeloproliferative neoplasm

KW - Polycythaemia vera

UR - http://www.scopus.com/inward/record.url?scp=84877814233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877814233&partnerID=8YFLogxK

U2 - 10.1111/bjh.12332

DO - 10.1111/bjh.12332

M3 - Article

C2 - 23573950

AN - SCOPUS:84877814233

VL - 161

SP - 688

EP - 694

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -